Investigational drug · Phase 2
BP1001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Myeloid Leukemia (AML).
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 7, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "BP1001"
First trial start
2016
May 2016
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BP1001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Myeloid Leukemia (AML)
Approved drugs for the same conditions: Acute myeloid leukemia · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "BP1001" as an intervention, largest first.
Bio-Path Holdings, Inc.Industry
NCT02781883 · 108 participants (planned) · Start May 2016 · Primary completion Dec 2027
Drug: BP1001 in combination with Ventoclax plus decitabine; BP1001 plus decitabine · For: Acute Myeloid Leukemia (AML)
Sites: Los Angeles, California; Augusta, Georgia; Fairway, Kansas · 9 sites in all
Bio-Path Holdings, Inc.Industry
NCT01159028 · 60 participants (planned) · Start Jun 2010 · Primary completion Mar 30, 2017
Drug: BP1001; BP1001 in combination with LDAC · For: Recurrent Adult Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome and 1 more
Sites: Houston, Texas
Bio-Path Holdings, Inc.Industry
NCT04196257 · 50 participants (planned) · Start Aug 19, 2022 · Primary completion Jul 2027
Drug: BP1001-A (Liposomal Grb2 Antisense Oligonucleotide); BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel · For: Solid Tumor, Adult; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms and 3 more
Sites: Silver Spring, Maryland; Detroit, Michigan; Dallas, Texas · 4 sites in all
Bio-Path Holdings, Inc.Industry
NCT02923986 · 0 participants · Start Sep 1, 2017 · Primary completion May 27, 2020
Drug: BP1001 (varying dose); BP1001 (fixed dose) and 1 more · For: Chronic Myelogenous Leukemia, Ph1-Positive; Acute Myeloid Leukemia; Myelodysplastic Syndrome
Sites: Houston, Texas
Newest research
PubMed records naming it or its code names, newest first.
- The conformational-condensate code of GRB2: State switching, spatial organization, and therapeutic windows.
Zhang J, Wang J, Huang W, et al. · Acta Pharm Sin B 2026
- The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery.
Gagliardi M, Ashizawa AT · Biomedicines 2021
- Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial.
Ohanian M, Tari Ashizawa A, Garcia-Manero G, et al. · Lancet Haematol 2018
- Liposomal delivery of nucleic acid-based anticancer therapeutics: BP-100-1.01.
Ashizawa AT, Cortes J · Expert Opin Drug Deliv 2015
- [Arterial blood pressure measurement with oscillometric instruments in newborns and infants].
Papadopoulos G, Oldörp B, Mieke S · Anaesthesist 1994
Also in development for Acute Myeloid Leukemia (AML)
- PBSS1113Phase 21 trial
Chaser Therapeutics, Inc. · Acute Myeloid Leukemia (AML), MDS (Myelodysplastic Syndrome)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.